CA2223397C - Nouveaux nor-pregnanes destines a induire des effets hypothalamiques - Google Patents
Nouveaux nor-pregnanes destines a induire des effets hypothalamiques Download PDFInfo
- Publication number
- CA2223397C CA2223397C CA002223397A CA2223397A CA2223397C CA 2223397 C CA2223397 C CA 2223397C CA 002223397 A CA002223397 A CA 002223397A CA 2223397 A CA2223397 A CA 2223397A CA 2223397 C CA2223397 C CA 2223397C
- Authority
- CA
- Canada
- Prior art keywords
- norpregna
- dien
- hydroxy
- trien
- pentaen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un procédé pour modifier la fonction hypothalamique chez un sujet. Le procédé consiste à administrer par voie nasale une vomérophérine humaine, par exemple le stéroïde 19-nor-prégnane, ou une composition pharmaceutique contenant une vomérophérine, de manière à ce que la vomérophérine se fixe sur un récepteur neuroépithélial spécifique. Le ou les stéroïdes sont, de préférence, administrés sous la forme d'une composition pharmaceutique contenant un ou plusieurs vecteurs acceptables sur le plan pharmaceutique. L'invention concerne également des compositions pharmaceutiques contenant lesdits stéroïdes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/485,615 US5792757A (en) | 1994-08-04 | 1995-06-07 | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
US08/485,615 | 1995-06-07 | ||
PCT/US1996/009665 WO1996040727A1 (fr) | 1995-06-07 | 1996-06-07 | Nouveaux nor-pregnanes destines a induire des effets hypothalamiques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2223397A1 CA2223397A1 (fr) | 1996-12-19 |
CA2223397C true CA2223397C (fr) | 2007-07-31 |
Family
ID=23928825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002223397A Expired - Fee Related CA2223397C (fr) | 1995-06-07 | 1996-06-07 | Nouveaux nor-pregnanes destines a induire des effets hypothalamiques |
Country Status (17)
Country | Link |
---|---|
US (3) | US5792757A (fr) |
EP (1) | EP0830369B1 (fr) |
JP (1) | JPH11507360A (fr) |
KR (1) | KR19990022640A (fr) |
CN (1) | CN1191542A (fr) |
AT (1) | ATE240344T1 (fr) |
AU (1) | AU724787B2 (fr) |
BR (1) | BR9609012A (fr) |
CA (1) | CA2223397C (fr) |
CZ (1) | CZ391597A3 (fr) |
DE (1) | DE69628163T2 (fr) |
EA (1) | EA000965B1 (fr) |
ES (1) | ES2197949T3 (fr) |
HU (1) | HUP9900887A3 (fr) |
NO (1) | NO975709L (fr) |
NZ (1) | NZ312303A (fr) |
WO (1) | WO1996040727A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057439A (en) * | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
US6117860A (en) * | 1994-08-04 | 2000-09-12 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia |
US6066627A (en) * | 1994-08-04 | 2000-05-23 | Pherin Corporation | Steroids as neurochemical initiators of change in human blood levels of LH |
US6331534B1 (en) | 1994-08-04 | 2001-12-18 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to alleviate pain |
US5922699A (en) * | 1996-06-07 | 1999-07-13 | Pherin Corporation | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
JP4450435B2 (ja) * | 1996-07-23 | 2010-04-14 | フィーリン・ファーマシューティカルズ・インコーポレイテッド | Pmsおよび不安の症状を緩和する、vnoにおける神経化学刺激物質としてのステロイド |
CA2330611A1 (fr) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Molecules bifonctionnelles et therapies basees sur celles-ci |
DE60045751D1 (de) | 1999-09-30 | 2011-04-28 | Harbor Biosciences Inc | Therapeutische Behandlung androgenrezeptorbedingter Leiden |
AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
US6555531B1 (en) * | 1999-12-30 | 2003-04-29 | Pherin Pharmaceuticals, Inc. | Weight promoting composition, method, and product |
US6413951B2 (en) * | 2000-06-27 | 2002-07-02 | Aventis Pharmaceuticals, Inc. | 20-fluoro-17(20)-vinyl steroids |
EP1372664A1 (fr) | 2001-03-01 | 2004-01-02 | Hollis-Eden Pharmaceuticals Inc. | Traitement de d ficiences affectant les globules sanguins |
EP1554572B1 (fr) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique |
US20040138187A1 (en) | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
CA2582231A1 (fr) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Analogues de steroides et leurs utilisations |
EP2671508B1 (fr) | 2005-04-28 | 2020-09-16 | Proteus Digital Health, Inc. | Système pharma-informatique |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
CA2698903A1 (fr) * | 2007-09-17 | 2009-03-26 | Human Pheromone Sciences, Inc. | Compositions de parfums et autres compositions qui contiennent des substances d'origine naturelle se trouvant dans les coraux |
CN102056484B (zh) * | 2008-04-09 | 2014-10-29 | 费林药业公司 | 用于热潮红的类固醇治疗 |
ES2919563T3 (es) | 2009-02-20 | 2022-07-27 | Enhanx Biopharm Inc | Sistema de administración de medicamentos a base de glutatión |
ES2942923T3 (es) | 2009-05-06 | 2023-06-07 | Laboratory Skin Care Inc | Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas |
LT2986623T (lt) * | 2013-04-17 | 2019-02-25 | Sage Therapeutics, Inc. | 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai |
CN107108689A (zh) * | 2014-09-17 | 2017-08-29 | 普瑞维卡斯有限公司 | C‑20类固醇化合物、其组合物和用于治疗包括震荡的创伤性脑损伤(tbi)的用途 |
DE102020204507A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Weichspüler mit aphrodisierend wirkenden Duftstoffen |
DE102020204505A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Wasch-/Pflegeartikel umfassend Pheromone |
DE102020204506A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Weichspüler mit Pheromonen |
DE102020204509A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Waschmittel mit Pheromonen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL287863A (fr) | ||||
US2840582A (en) * | 1953-08-31 | 1958-06-24 | Searle & Co | Derivatives of 13-methyl-17-hydroxy-1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17-tetradecahydro-15h-cyclopenta[a]phenanthren-3-ones |
DE1297603B (de) | 1964-08-08 | 1969-06-19 | Schering Ag | Verfahren zur Herstellung von 3-Keto-delta 17(20)-pregnenen |
ES319318A1 (es) | 1964-11-13 | 1966-10-16 | American Cyanamid Co | Procedimiento para la preparaciën de una composiciën anticonceptiva |
US3385849A (en) * | 1965-07-01 | 1968-05-28 | Hoffmann La Roche | Process for the preparation of 17beta-pregnanes from 17-oxo-steroids |
US3492318A (en) * | 1968-01-22 | 1970-01-27 | Syntex Corp | Cyclopropenyl androstanes |
US3682983A (en) * | 1969-11-12 | 1972-08-08 | Klaus Prezewowsky | Preparation of {66 {11 {11 -17 ethinyl steroids |
FR2097045A1 (en) | 1970-07-30 | 1972-03-03 | Roussel Uclaf | 17-ethynylgon-4-en-3-ones - with progestomimetic activity useful as contraceptives and for gynaecological disorders |
US3681410A (en) * | 1970-08-07 | 1972-08-01 | Syntex Corp | Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof |
US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
US5155045A (en) | 1985-01-25 | 1992-10-13 | Trustees Of The University Of Penn. | Use of male essence to alter female endocrine response |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
JP2578369B2 (ja) * | 1989-05-09 | 1997-02-05 | ポーラ化成工業株式会社 | 芳香組成物 |
GB8912043D0 (en) * | 1989-05-25 | 1989-07-12 | Beecham Group Plc | Novel compounds |
US5278141A (en) * | 1992-03-24 | 1994-01-11 | Erox Corporation | Fragrance compositions containing human pheromones |
US5272134A (en) * | 1992-03-24 | 1993-12-21 | Erox Corporation | Fragrance compositions and other compositions which contain human pheromones |
-
1995
- 1995-06-07 US US08/485,615 patent/US5792757A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 US US08/660,297 patent/US5962443A/en not_active Expired - Lifetime
- 1996-06-07 EP EP96923241A patent/EP0830369B1/fr not_active Expired - Lifetime
- 1996-06-07 KR KR1019970709215A patent/KR19990022640A/ko not_active Application Discontinuation
- 1996-06-07 EA EA199800052A patent/EA000965B1/ru not_active IP Right Cessation
- 1996-06-07 JP JP9501937A patent/JPH11507360A/ja active Pending
- 1996-06-07 DE DE69628163T patent/DE69628163T2/de not_active Expired - Lifetime
- 1996-06-07 CA CA002223397A patent/CA2223397C/fr not_active Expired - Fee Related
- 1996-06-07 AU AU63807/96A patent/AU724787B2/en not_active Ceased
- 1996-06-07 HU HU9900887A patent/HUP9900887A3/hu unknown
- 1996-06-07 AT AT96923241T patent/ATE240344T1/de not_active IP Right Cessation
- 1996-06-07 NZ NZ312303A patent/NZ312303A/xx unknown
- 1996-06-07 ES ES96923241T patent/ES2197949T3/es not_active Expired - Lifetime
- 1996-06-07 CN CN96195782A patent/CN1191542A/zh active Pending
- 1996-06-07 BR BR9609012-0A patent/BR9609012A/pt unknown
- 1996-06-07 WO PCT/US1996/009665 patent/WO1996040727A1/fr not_active Application Discontinuation
- 1996-06-07 CZ CZ973915A patent/CZ391597A3/cs unknown
-
1997
- 1997-12-05 NO NO975709A patent/NO975709L/no not_active Application Discontinuation
-
1998
- 1998-08-11 US US09/131,998 patent/US6242619B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU6380796A (en) | 1996-12-30 |
EA000965B1 (ru) | 2000-08-28 |
HUP9900887A2 (hu) | 1999-08-30 |
NO975709L (no) | 1998-02-05 |
US5792757A (en) | 1998-08-11 |
EP0830369B1 (fr) | 2003-05-14 |
DE69628163D1 (de) | 2003-06-18 |
WO1996040727A1 (fr) | 1996-12-19 |
ES2197949T3 (es) | 2004-01-16 |
HUP9900887A3 (en) | 1999-11-29 |
US5962443A (en) | 1999-10-05 |
ATE240344T1 (de) | 2003-05-15 |
MX9709693A (es) | 1998-10-31 |
DE69628163T2 (de) | 2004-04-01 |
NZ312303A (en) | 2000-01-28 |
US6242619B1 (en) | 2001-06-05 |
CN1191542A (zh) | 1998-08-26 |
EP0830369A1 (fr) | 1998-03-25 |
BR9609012A (pt) | 1999-12-14 |
EA199800052A1 (ru) | 1998-08-27 |
NO975709D0 (no) | 1997-12-05 |
CZ391597A3 (cs) | 1998-06-17 |
EP0830369A4 (fr) | 1999-06-09 |
JPH11507360A (ja) | 1999-06-29 |
AU724787B2 (en) | 2000-09-28 |
CA2223397A1 (fr) | 1996-12-19 |
KR19990022640A (ko) | 1999-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2223397C (fr) | Nouveaux nor-pregnanes destines a induire des effets hypothalamiques | |
AU703524B2 (en) | Pregnanes and cholanes as neurochemical initiators of change in hypothalamic function | |
WO1996040727A9 (fr) | Nouveaux nor-pregnanes destines a induire des effets hypothalamiques | |
AU732960B2 (en) | 19-NOR-cholane steroids as neurochemical initiators of change in human hypothalamic function | |
CA2250309C (fr) | Steroides comme initiateurs neurochimiques de modification des concentrations en lh ou en fsh dans le sang humain | |
CA2165325A1 (fr) | Steroides a base d'androstane, initiateurs neurochimiques de changements dans la fonction hypothalamique chez l'homme; compositions pharmaceutiques et methodes connexes | |
WO1997046574A9 (fr) | Steroïdes de 19-nor-cholane utiles comme initiateurs neurochimiques d'une modification de la fonction hypothalamique humaine | |
EP0914165B1 (fr) | Steroides utilises en qualite de stimulateurs neurochimiques de l'organe vomero-nasal et permettant de soulager les symptomes premenstruel | |
WO1997036596A9 (fr) | Steroides comme initiateurs neurochimiques de modification des concentrations en lh ou en fsh dans le sang humain | |
AU705422B2 (en) | Novel estrenes for inducing hypothalamic effects | |
AU3732995A (en) | Novel androstanes for inducing hypothalamic effects | |
US6352980B1 (en) | Estrenes for inducting hypothalamic effects | |
CA2165324A1 (fr) | Steroides a base d'estrene, initiateurs neurochimiques de changements dans la fonction hypothalamique chez l'homme; compositions pharmaceutiques et methodes connexes | |
CA2196690C (fr) | Pregnanes et cholanes en tant qu'initiateurs neurochimiques servant a induire des modifications de la fonction hypothalamique | |
US6140316A (en) | Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions | |
MXPA97009693A (en) | Novedosos nor-pregnanos, to induce hipotalami effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140609 |